Simulations Plus (NASDAQ:SLP) Stock Passes Above 200-Day Moving Average – Here’s Why

Simulations Plus, Inc. (NASDAQ:SLP) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $15.44 and traded as high as $18.25. Simulations Plus shares last traded at $18.21, with a volume of 504,876 shares changing hands.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. William Blair cut Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. TD Cowen decreased their price target on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, April 10th. Craig Hallum downgraded Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective for the company. in a research note on Thursday, June 18th. Finally, Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Seven equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Simulations Plus presently has a consensus rating of “Reduce” and a consensus target price of $17.25.

Simulations Plus Stock Performance

The business has a fifty day moving average of $16.96 and a two-hundred day moving average of $15.44. The firm has a market cap of $369.11 million, a price-to-earnings ratio of 45.62 and a beta of 1.30.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.07. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.The business had revenue of $21.89 million during the quarter, compared to analysts’ expectations of $20.90 million. On average, equities research analysts forecast that Simulations Plus, Inc. will post 0.8 earnings per share for the current year.

Insider Activity

In other news, Director Walter S. Woltosz sold 4,177 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total value of $77,023.88. Following the sale, the director directly owned 3,202,131 shares in the company, valued at $59,047,295.64. This represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in shares of Simulations Plus in the second quarter worth $25,000. Quarry LP purchased a new stake in Simulations Plus during the 3rd quarter worth about $28,000. GAMMA Investing LLC increased its position in Simulations Plus by 26.0% during the 2nd quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock worth $52,000 after purchasing an additional 585 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Simulations Plus by 59.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock valued at $53,000 after purchasing an additional 1,669 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new position in Simulations Plus in the 1st quarter valued at about $54,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.